Galderma is a privately-held company. It debuted as the world’s largest independent global dermatology company on October 1, 2019. The acquisition from Nestlé S.A. was led by a consortium comprising the EQT VIII fund (“EQT”), Luxinva (a wholly-owned subsidiary of Abu Dhabi Investment Authority, “ADIA”), PSP Investments and other renowned institutional investors.
Galderma’s investors are advised by a seasoned Advisory Committee composed of sector-specific, ex-CEO industry leaders:
In 1987, Thomas started his career at Reemtsma and moved to Pepsi-Cola, Germany in 1991, where he held various positions in marketing and sales. In 1997, he became General Manager at Novartis Nutrition Germany and Austria. In 1998, he took over the global CEO role of the Nutrition Division and became a Member of the Executive Committee of Novartis. From 2000 until 2007, he was CEO of Novartis Pharmaceuticals and from 2007 to 2008 CEO of Novartis Consumer Heath. From 2009 to 2018, he was CEO of ProSiebenSat.1 Media. Since 2017, Thomas has been acting as a professional Non-Exec Board Member advising a multiple number of businesses and owners.
Thomas studied Psychology at the University of Hamburg.
Sheri has 30+ years of experience in the healthcare space working for Johnson & Johnson as Vice Chairperson of JNJ with responsibility for Pharma and Consumer. Furthermore, Sheri has worked in MedTech and served as Worldwide Chairperson of Surgical Care.
She has held the CEO position for Avon products with significant experience in emerging markets, experience in M&A and running complex global structures. She sits on various boards in the healthcare industry.
Sheri holds a BSc degree in Textile Chemistry from University of Massachusetts Dartmouth; MS degree in Chemical Engineering from Princeton University and MBA from Rutgers University.
STEFAN F. HEIDENREICH
Stefan started his career as a Brand Manager at Procter & Gamble. After several leadership positions at Reckitt Benckiser, Bertelsmann and the Hero Group, he was the CEO of Hero from 2004 to 2011. In 2012 Heidenreich became CEO of Beiersdorf. In the same year he started the company strategy Blue Agenda which focused on NIVEA. With this compass and the increasing efficiency in operations under Heidenreich, the company’s value more than doubled under his leadership. On December 31st, 2018 Stefan F. Heidenreich retired from the Board.
Since 2020, Stefan is an active investor, senior advisor and board member for several international companies.
Dan Browne has more than 30 years of entrepreneurial and executive leadership experience in the healthcare industry. He has led the development of multiple innovative products that are leaders in their category, as well as critical business development and partnership activities. He is the Co-Founder and former President & Chief Executive Officer of Revance Therapeutics, Inc. He brought the company from early-stage incubator in 2002 to a highly successful IPO in 2014. During the course of his tenure, he led clinical, regulatory/quality, finance and commercial operations. Prior roles include President & CEO of Neomend, President & CEO of Prograft Medical, and Business Leader at WL Gore & Associates, Inc.
Since 2020, Dan has been a board member to AVAVA and Rythera Therapeutics. Dan holds an MBA from Pepperdine Graziadio Business School.
MARIA TERESA HILADO
A financial management specialist with over 30 years’ experience, Ms. Hilado brings a proven track record across several global corporations and brands. Her background includes pharmaceuticals, consumer products and industrials.
She most recently served as Executive Vice President and Chief Financial Officer at global pharmaceutical company Allergan PLC, from 2014 until her retirement in 2018. Prior to this, Ms. Hilado was Senior Vice President, Finance and Treasurer of PepsiCo Inc.; Vice President and Treasurer for Schering-Plough Corp.; and held several leadership roles at General Motors Company.
She holds a Bachelor of Science in Management Engineering from Ateneo de Manila University in the Philippines and an MBA from the University of Virginia Darden School of Business.
Karen Ling has a strong track record in executive roles guiding compensation, culture and program strategies. She is an accomplished global human resources executive with over 25 years’ experience in the pharmaceutical sector.
Ms. Ling recently retired from her role as Executive Vice President and Chief Human Resources Officer of American International Group, Inc. (AIG), where she oversaw all aspects of human capital management. Before joining AIG, she served as Executive Vice President and Chief Human Resources Officer at Allergan. There, she unified multiple acquisitions and was instrumental in various innovative compensation programs.
Ms. Ling currently sits on the Board of Directors of iRhythm Technologies (NASDAQ: IRTC) and is Chair of its Compensation and Talent Management Committee. She is also a member of the Board of Directors at Mallinckrodt (NYSE: MNK) and of its Human Resources and Compensation Committee. Ms. Ling holds a Juris Doctor from the Boston University School of Law and earned her undergraduate degree at Yale University.